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Abstract
Background: A beneficial effect of gentamicin supplemented mesh material on tissue integration is known. To
further elucidate the interaction of collagen and MMP-2 in chronic foreign body reaction and to determine the
significance of the MMP-2-specific regulatory element (RE-1) that is known to mediate 80% of the MMP-2 promoter
activity, the spatial and temporal transcriptional regulation of the MMP-2 gene was analyzed at the cellular level.
Methods: A PVDF mesh material was surface modified by plasma-induced graft polymerization of acrylic acid
(PVDF+PAAc). Three different gentamicin concentrations were bound to the provided active sites of the grafted
mesh surfaces (2, 5 and 8 μg/mg). 75 male transgenic MMP-2/LacZ mice harbouring the LacZ reporter gene under
control of MMP-2 regulatory sequence -1241/+423, excluding the RE-1 were randomized to five groups. Bilateral of
the abdominal midline one of the five different meshes was implanted subcutaneously in each animal. MMP-2
gene transcription (anti-ß-galactosidase staining) and MMP-2 protein expression (anti-MMP-2 staining) were
analyzed semiquantitatively by immunohistochemistry 7, 21 and 90 days after mesh implantation. The collagen
type I/III ratio was analyzed by cross polarization microscopy to determine the quality of mesh integration.
Results: The perifilamentary ß-galactosidase expression as well as the collagen type I/III ratio increased up to the
90
th day for all mesh modifications, whereas no significant changes could be observed for MMP-2 protein
expression between days 21 and 90. Both the 5 and 8 μg/mg gentamicin group showed significantly reduced
levels of ß-galactosidase expression and MMP-2 positive stained cells when compared to the PVDF group on day 7,
21 and 90 respectively (5 μg/mg: p < 0.05 each; 8 μg/mg: p < 0.05 each). Though the type I/III collagen ratio
increased over time for all mesh modifications significant differences to the PVDF mesh were only detected for the
8 μg/mg group at all 3 time points (p < 0.05 each).
Conclusions: Our current data indicate that lack of RE-1 is correlated with increased mesh induced MMP-2-gene
expression for coated as well as for non-coated mesh materials. Gentamicin coating reduced MMP-2 transcription
and protein expression. For the 8 μg/mg group this effect is associated with an increased type I/III collagen ratio.
These findings suggest that gentamicin is beneficial for tissue integration after mesh implantation, which possibly
is mediated via RE-1.
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Modern hernia surgery is no longer imaginable without
the application of mesh prosthesis leading to millions of
biomaterial implantations each year worldwide [1-3].
Implantation of alloplastic mesh material results in an
inflammatory reaction to foreign bodies of a different
nature that is surprisingly constant, characterized by a
rapid accumulation of huge numbers of phagocytic cells,
in particular blood monocytes and tissue-derived macro-
phages [4-6]. This type of inflammation is known as for-
eign body reaction (FBR), which is characterized by a
transcriptionally induced overexpression of the matrix
metalloproteinases 2 (MMP-2) [7-9].
MMP-2 (gelatinase A) plays an essential role in angio-
genesis, inflammation, and fibrosis, and is necessary for
a proper wound healing [10,11]. Advanced investigations
by Jansen et al. revealed that mesh implantation med-
iates enhanced MMP-2 gene transcription with conco-
mitantly up-regulated MMP-2 protein synthesis and
enzymatic activity, thus resulting in a chronic inflamma-
tory reaction [9]. Interestingly, a close correlation
between MMP-2 expression and collagen formation and
degradation is evident establishing a role for MMP-2 in
critical events during wound repair [12]. Affecting
MMP-2 by modification of either the polymer itself or
by coating of the mesh material is suggested to be a
potential approach to reduce the chronic inflammatory
reaction to alloplastic mesh materials, and thereby to
reduce long-term complications like mesh shrinkage,
migration, adhesion and in particular chronic pain
[13,14]. Furthermore, it is well known that the quality of
perifilamentary scar formation which is characterized by
the collagen type I/III ratio is of major impact to mini-
mize the risk of complications or even to avoid the
development of a recurrent hernia [15,16].
In a previously published study gentamicin coated
polyvinylidenfluoride (PVDF) mesh material was
detected to improve tissue integration due to an
increased type I/III collagen ratio and a reduced MMP-2
protein expression [17]. However, our model analysing
MMP-2 gene expression in transgenic mice revealed dis-
tinct MMP-2 promoter activation dependent on the
course of time and on the concentration of gentamicin
[17]. To further elucidate our proven beneficial effect of
biomaterial supplementation on foreign body reaction
and tissue integration an in-depth understanding of the
gentamicin induced enhancement of MMP-2 is neces-
sary. Therefore, gentamicin coated mesh materials with
three different concentrations per unit of weight (μg/
mg) were implanted in transgenic reporter mice har-
bouring a ß-galactosidase reporter gene (LacZ) driven
by the regulatory sequences of the MMP-2 gene. To
determine the significance of the response element-1
(RE-1) that extends from -1282/-1322, F8del mice were
created that harbour MMP-2 regulatory sequence
-1241/+423, thereby excluding the RE-1. The spatial and
temporal transcriptional regulation of the MMP-2 gene
was analyzed at the cellular level.
Methods
Animal studies
The experiments were officially approved by the local
Animal Care and Use Review Committee (50.203.2-
AC46, 38/02). All animals received humane care in
accordance with the requirements of the German
Tierschutzgesetz, §8 Abs. 1 and in accordance to the
Guide for the Care and Use of Laboratory Animals pub-
lished by the National Institute of Health.
A total of 75 male MMP-2/LacZ transgenic CD1-tg
mice (mean body weight 28.2 ± 2.0 g) were randomly
divided into five groups according to the type of mesh
material used. All animals were kept under standardized
conditions: temperature between 22°C and 24°C; relative
humidity 50-60%; 12 h of light following 12 h of dark-
ness. The animals had free access to food and water.
Food was withdrawn 12 h before and after surgery. All
operations were carried out under general anesthesia
and aseptic and sterile surgical conditions.
MMP-2/LacZ transgenic mice model
The mice strain used as animal model has been
described recently [9,11,17,18]. In brief, mouse strain F8
harbour a b-galactosidase reporter gene (LacZ) under
control of MMP-2 regulatory sequences -1686/+423 that
extend to the middle of the second exon. Thereby cells
with MMP-2 promoter activity can be detected by a
monoclonal anti-b-galactosidase antibody. A part of this
regulatory sequence is the response element-1 (RE-1)
that extends from -1282/-1322. In previous data a cru-
cial role for the enhancer element RE-1 was proven in
injury-induced MMP-2 transcription of the skin (11). To
determine the significance of the response element-1
(RE-1) in foreign body reaction and tissue integration in
response to the surface modified biomaterials, the
sequences -1282/-1322 were deleted and F8del mice
were created that harbour MMP-2 regulatory sequence
-1241/+423, thereby excluding the RE-1. Seventy five of
those mice were used for the investigations.
Mesh material
Overall five different mesh modifications with 0.5 × 0.5
cm in size were implanted: PVDF, a low-weight, large
porous and elastic mesh made of polyvinylidenfluoride
monofilaments (FEG Textiltechnik mbH, Aachen, Ger-
many) was the basic prosthetic material for the con-
struction of all mesh samples. Plasma-induced graft
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try and morphology of the PVDF mesh samples [19].
Immediately after treatment, oxygen was introduced
into the chamber to generate hydroperoxide as well as
other functional groups on the sample surface (FEG
Textiltechnik mbH, Aachen, Germany). Thereafter, graft
polymerization of polyacrylic acid onto the plasma trea-
ted surface of the PVDF mesh samples was performed
resulting in a polyacrylic acid monomer layer on the
surface (PVDF + PAAc). The antibiotic gentamicin was
bound to the active sites of the grafted mesh surface in
three different concentrations respectively (PVDF +
PAAc +2 μg/mg Gentamicin; PVDF + PAAc + 5 μg/mg
Gentamicin, and PVDF + PAAc + 8 μg/mg Gentamicin).
The efficacy of the antimicrobial mesh samples investi-
gated by agar diffusion test, the gentamicin release from
the mesh surface, and the cytotoxic side effects after
direct contact to L929 mouse fibroblasts (BioWhittaker
BE71-131F) were tested in a previously published study
[20].
Surgical procedure and observation periods
Operations were carried out under sterile surgical condi-
tions and general anaesthesia by intramuscular adminis-
tration of ketamine (Ketamin 10%, Sanofi-Ceva,
Düsseldorf, Germany) and xylazine (Rompun 2%, Bayer,
Leverkusen, Germany). Following the induction of
anaesthesia, the skin was shaved and disinfected with
polyvidone iodine solution (Braunosan Vet
®,B .B r a u n
Vet Care GmbH, Tuttlingen, Germany). Full thickness
dermal incisions extending over 1.5 cm were performed
1 cm bilateral of the abdominal midline. Polymers (size:
0.5 × 0.5 cm) were implanted subcutaneously 1 cm dis-
tal of the xiphoid. In each animal two of the same poly-
meric mesh materials were implanted bilateral of the
abdominal midline respectively. Following mesh implan-
tation skin closure was obtained with 3/0 polypropylene
(Prolene
®, Ethicon Inc., Somerville, NJ, USA) single
sutures. No additional antibiotic treatment was given
before or during the experiments. Throughout the
whole observation period all animals were objectively
controlled and underwent daily clinical investigation to
assess local and systemic complications. 7, 21 and 90
days after mesh implantation n = 5 animals in each
group were euthanized by isoflurane (Attane™,M I N -
RAD INC., Buffalo, NY, USA) asphyxation and decapita-
tion. Tissue specimens for histological and
immunohistochemical observations were immediately
fixed in 10% formaldehyde.
Histological assessment and immunohistochemical
analysis
Briefly, all histological and immunohistochemical inves-
tigations including the cross polarization microscopy
were performed in the same manner as previously
described [17].
Statistical analysis
Statistical analysis was carried out using the Statistical
Package for Social Sciences (SPSS, Version 17.0, Chi-
cago, IL, USA) software. Data were organized according
to the types of meshes used (PVDF; PVDF + PAAc;
PVDF + PAAc + 2 μg / m g ;P V D F+P A A c+5μg/mg;
PVDF + PAAc + 8 μg/mg), and to the duration of
implantation (7, 21, 90 days). Analysis of histological
and immunohistochemical parameters were performed
using the Mann-Whitney U test. P values of < 0.05 were
considered to be significant. All data are presented as
mean ± standard deviation if not otherwise mentioned.
Results
None of the animals died during the investigation and
none of the animals developed any signs of local or gen-
eral inflammation.
MMP-2 protein expression
Apart from the PVDF + PAAc group, MMP-2 expres-
sion significantly decreased for all other mesh groups
comparing day 7 to day 21 (PVDF: p = 0.016; 2 μg/mg:
p = 0.016; 5 μg/mg: p = 0.016; 8 μg/mg: p = 0.029). In
the later course of time the MMP-2 expression was sig-
nificantly reduced only for the 5 and 8 μg/mg group
comparing day 21 to day 90 (5 μg/mg: p = 0.016; 8 μg/
mg: p = 0.029) (Figure 1 and 2A).
Both the 5 and 8 μg/mg mesh material showed signifi-
cantly reduced levels of MMP-2 positive stained cells
when compared to the pure PVDF group on day 7, 21
and 90 (5 μg / m g :p=0 . 0 1 6 ,p=0 . 0 1 6 ,p=0 . 0 1 6 ;8μg/
mg: p = 0.029, p = 0.016, p = 0.029). Except for day 7
the 2 μg/mg group likewise showed a significant reduc-
tion of MMP-2 protein expression compared to the
pure PVDF group on day 21 (p = 0.016) and 90 (p =
0.032) (Figure 1 and 2A).
MMP-2 promoter activity (ß-galactosidase)
To detect the perifilamentary MMP-2 promoter activity
we analyzed the ß-galactosidase expression (Figure 2B).
In contrast to the MMP-2 expression MMP-2 promoter
activity was reciprocal and increased discrete over time
for all mesh modifications. Certainly a significant
increase of ß-galactosidase expression could be detected
only for the 5 μg/mg group from day 7 to day 21 (5 μg/
mg: p = 0.026). The enhancement of the MMP-2 pro-
moter activity was significant for the PVDF (p = 0.016),
2 μg/mg (p = 0.008) and 8 μg/mg (p = 0.029) group
comparing day 21 and day 90 (Figure 2B and 3).
On postoperative day 90 a significant reduction of ß-
galactosidase stained cells was observed for all
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the pure PVDF group (2 μg/mg: p = 0.016; 5 μg/mg: p =
0.016; 8 μg/mg: p = 0.029). On day 21 the MMP-2 pro-
moter activity showed any significant differences com-
paring the groups. Only the 8 μg/mg group revealed a
significant reduced expression of ß-galactosidase on day
7 compared to the pure PVDF group (p = 0.029) (Figure
2B and 3).
Collagen type I/III ratio
The collagen type I/III ratio was investigated to evaluate
the quality of perifilamentary collagen deposition. This
ratio ascended in each mesh group in the course of
time. Comparing day 7 to day 21, the collagen type I/III
ratio increased significantly in each mesh group except
for the PVDF + PAAc group (PVDF: p = 0.016; 2 μg/
mg: p = 0.016; 5 μg/mg: p = 0.016; 8 μg/mg: p = 0.029).
A significantly increased collagen type I/III ratio was
detected comparing day 21 to day 90 for each mesh
group apart from the PVDF group (PVDF + PAAc: p =
0.036; 2 μg/mg: p = 0.008; 5 μg/mg: p = 0.016; 8 μg/mg:
p = 0.029) (Figure 4).
Only the 8 μg/mg group showed significantly elevated
values 7, 21 and 90 days after implantation when com-
pared to the pure PVDF group (p = 0.029, p = 0.016, p
=0 . 0 2 9 ) .T h e2μg / m gg r o u pa sw e l la st h e5μg/mg
group exhibited a significantly improved collagen type I/
III ratio in comparison with the PVDF group only on
day 90 (p = 0.016 and p = 0.016). Additionally the col-
lagen type I/III ratio was significantly elevated in the 2
μg/mg group (p = 0.029) on day 7, and in the PVDF +
PAAc group (p = 0.036) on day 21 compared to the
PVDF group, respectively (Figure 4).
Discussion
To reinforce the abdominal wall with mesh material is
the gold standard in hernia repair and has lead to a con-
siderable reduction of recurrence rates, however their
implantation is associated with acute and chronic side
effects like seroma and as long-term complication in
particular chronic pain [13,14,21-24]. In particular long-
term complications are supposed to be the consequence
of a foreign body reaction (FBR), which is induced by
every implantation of non-absorbable polymeric mesh
Figure 1 Histogram illustrating the percentage of MMP-2 positive stained cells detected in the perifilamentary area in each mesh
group (represented as mean ± standard deviation, significant differences are marked (*)).
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inflammatory reaction, which is marked by an activation
of cytokine cascades and proteases, such as the matrix
metalloproteinases 2 (MMP-2) [27,28]. This well known
continuous expression of MMP-2 in foreign body reac-
tion can also be observed in our study (Figure 1)
whereas MMP-2 expression after injury is normally
restricted to the proliferative phase of wound healing.
For this reason the inhibition of inflammation and as a
consequence the normalization of MMP-2 expression is
suggested as a new therapeutical approach to optimize
mesh integration and to reduce mesh related complica-
tions [15,20]. By mesh modification with the aminogly-
coside antibiotic gentamicin we found a time dependent
reduction of the MMP-2 protein synthesis in a preced-
ing study [17]. Especially, the perifilamentary MMP-2
protein expression was significantly diminished by mesh
coating with a concentration of 8 μg/mg gentamicin at
each time point. In previously published studies this
potential impact of gentamicin on MMP-2 expression
was likewise demonstrated, but in contrast to these
results our current findings provide evidence for a pre-
sumably dose-dependent down-regulation of the MMP-
2 [29,30]. Our current survey confirms the previously
proven beneficial effect of gentamicin supplemented
polyvinylidenfluoride (PVDF) mesh materials on tissue
integration and foreign body reaction due to an
improved collagen type I/III ratio and reduced MMP-2
protein expression.
However, and in contrast to our previous findings the
MMP-2 promoter activity increased reciprocally to the
MMP-2 protein expression, thereby suggesting that gen-
tamicin represses the MMP-2 promoter in F8del mice.
This ostensible controversy with an increased ß-galacto-
sidase expression in F8del mice may be explained most
suitable as follows. It is known that the extent of MMP-
2 expression and enzymatic activity is regulated at the
transcriptional, translational, and post-translational
Figure 2 Immunohistochemical images representing MMP-2 staining following implantation of a PVDF mesh (A) and a PVDF+PAAc+8
μg/mg mesh (C). Figure (B) demonstrates ß-galactosidase staining following implantation of a PVDF mesh and a PVDF+PAAc+8 μg/mg mesh
(D) (magnification 200 fold, 90 days postoperatively respectively).
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MMP-2 gene transcription that reside up to -1686 base
pairs (bps) relative of the translational start site have
been identified [32,34-37]. A strong enhancer element
named response element-1 (RE-1) is located at -1282/-
1322 bps of the mice MMP-2 gene [32], which is evolu-
tionarily conserved and is similarly operative within the
human gene at -1657/-1619 bps relative to the tran-
scriptional start site [38]. F8 mice harbor MMP-2 regu-
latory sequence -1686/+423, including the RE-1, showed
both a reduced MMP-2 protein expression and promo-
ter activity with presence of gentamcin [17]. On the
other hand the F8del mice that were investigated in the
present study harbour MMP-2 regulatory sequence
-1241/+423, excluding the RE-1. This mouse strain
revealed a reduced MMP-2 protein expression but a ris-
ing MMP-2 promoter activity in all mesh groups. Taken
into account the preceding and current results, RE-1
mostly acts as a repressor of mesh induced MMP-2
transcription. Though we could confirm that gentamicin
is beneficial for tissue integration regarding reduced
MMP-2 expression and enhanced type I/III collagen
ratio, the same repressive function of RE-1 could be
detected for both the coated and the uncoated mesh
group.
It is known that the aminoglycosides like gentamicin
are able to penetrate eukaryotic cell membrane and it is
known that beside its antibacterial activity gentamicin
interacts with intracellular molecules thereby influencing
intracellular pathways, which might explain the reduced
MMP-2 expression and gene regulation [39,40].
Although the exact molecular mechanisms are not yet
unraveled, our findings support the hypothesis that the
observed down-regulation of MMP-2 is finally mediated
by inhibition of the MMP-2 promoter.
Certainly it remains unclear which transcription fac-
tors mediate the down-regulation of mesh induced
MMP-2 expression. At least distinct transcription fac-
tors have been shown to bind to the RE-1. These
include activating protein-2 (AP 2) [37], Y-box protein-1
Figure 3 Histogram representing the perifilamentary ß-galactosidase expression in each mesh group (represented as mean ±
standard deviation, significant differences are marked (*)).
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scription factor 3 (Stat3) [41], and p53 [36]. In a pre-
viously published study by Jansen et al. it could be
shown that macrophages that are adjacent to the mesh
filaments play a crucial role for mesh induced MMP-2
expression [9]. Therefore, the gentamicin mediated
down-regulation of MMP-2 transcription in our study
might be due to a cellular effect, e.g. by reducing infil-
tration or activation of macrophages or other inflamma-
tory cells that are involved in MMP-2 expression. The
results of our current investigation further support the
hypothesis of an intercellular crosstalk between inflam-
matory cell like macrophages and fibroblasts via MMP-2
regulation in the process of foreign body reaction.
Restrictively, it has to be noted that the collagen type
I/III ratio was significantly elevated for each gentamicin
concentration on day 90, whereas on postoperative day
7 and 21 merely the mesh with a coating of 8 μg/mg
gentamicin constantly resulted in a significant improve-
ment of the collagen ratio. As already mentioned a
dose-dependent effect of gentamicin is possibly the rea-
son for an insignificant or even negative effect on col-
lagen formation and degradation. This is in line with a
study by Asch and Farnham who demonstrated a dose-
dependent effect of gentamicin on the protease activity
of collagenase derived from Clostridium histolyticum
[42].
Conclusion
The present results again demonstrate a beneficial effect
of gentamicin on chronic foreign body reaction by mod-
ulation of MMP-2 gene transcription that may be a fea-
sible approach to optimize mesh integration into the
abdominal wall, and ultimately to improve the long-
term outcome following hernia mesh repair. However,
animal models have their natural limitations, and results
cannot be extrapolated directly to the situation in
humans. Therefore, clinical trials are needed to verify
the suggested beneficial effect of gentamicin, and further
experimental studies are needed to elucidate the exact
Figure 4 Histogram demonstrating the perifilamentary collagen type I/III ratio in each mesh group (represented as mean ± standard
deviation, significant differences are marked (*)).
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transcription.
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